A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers
Latest Information Update: 16 Feb 2019
At a glance
- Drugs Cimlanod (Primary)
- Indications Decompensated heart failure
- Focus Adverse reactions; First in man
- Sponsors Cardioxyl Pharmaceuticals
- 31 Jan 2019 Results published in the Journal of Clinical Pharmacology
- 28 Jul 2014 Positive results have been reported in a Cardioxyl Pharmaceuticals media release.
- 28 Jul 2014 Status changed from recruiting to completed, according to a Cardioxyl Pharmaceuticals media release.